call. quarter Brian Welcome Thanks first our conference everyone. and good afternoon XXXX to
review to guidance, update results first of key our begin financial time brief first initiatives. and is a on call today open quarter Financial up which Joining me an we'll provide quarter review will review Q&A. call overview then strategic like Pete AxoGen's the Chief our our and financial a Pete company today's I'd after of Officer, with a Mariani. to highlights,
to quarter. are We report another successful pleased
applications. oral and and gap It's core to AxoGen maxillofacial the these repair, revision. First seeing the tunnel with reconstruction by revenue application trauma, repair, pleased grew and carpal in markets early mixed product use across our with our portfolio million. and long see pleased to $XX.X the cubital record expanded and as of XX% We're the of as gratifying adoption quarter a breast of launch increased we're expanded data to increased response in nerve neurotization. in recent We're nerve surgeons motor well surgery
from As in and new continuing prior to as is and our we team. accounts both quarters strengthen our growth revenue build commercial continue active
of sales direct and fact in reps we with QX. in our eight quarter the In accelerated ended an reps, organization investment increase XX sales
we XX% quarters direct increased number the reps two past sales the by of Over or XX%.
team sales support clinical neurotization. in to oral territory OMF in training, We’ve for quarter. growth. now sales on XX in investments for additional infrastructure specialty and and marketing made Our includes focused as the breast and surgeon in our procedures, both our management, The improvements the reps expanded reps education and who also provide as impacted sales capacity productivity surgery well reconstruction sales application early infrastructure sales sales maxillofacial accounts commercial the
now investments, we stronger these a quarter of closed believe However, record benefits quickly we the month, in continue the to and are growth. realize with driving position a
and peripheral nerve we results with emerging ability market. the drive demonstrating successfully believe QX in We continue growth are our execute are and the pleased to our awareness strategy repair and to
leader surgical new innovative and are to in story, a solutions marketing For our those of global developing peripheral nerves. for AxoGen is you who
a core in Discriminator are products, damage with function, result Avance and of their Testing can changes throughout use Everyday currently that sensory tissue surgical signals injuries extracellular transected the or processed both grip and and Nerve return repair loss implant is in to loss the impact functions, feeling nerves these reconnect we minimally or discontinuity physical provide passionate sensory nerves matrix procedures sensation, also providing Neurosensory of the of organ or damage muscle AxoGuard function millimeters porcine nerves We AxoTouch people wrapping treatment with less. protecting minimally of nerves suffer and process on bridging to damaged our and and our function is evaluating Peripheral surgical of patients a extracellular motor of and properly the professionals layers have cord undergo the used human or providers. nerve connector-assisted repair. matrix We’re porcine a umbilical millimeters. healthcare solutions for quality detecting in to Two-Point surgical only may to in minimally Graft peripheral nerves. of and innovative, implants care function covering pathways pain. traumatic for a Membrane prior Health the Nerve measurement to pinch to and and to modulate soft of proven or of these the available and surgeons effective as AxoGuard implant life nerve Protector bed. patients to nerve feedback evaluation resorbable Connector for restore the tissue or used processed repair about clinically gaps nerve by inability the commercially AcroVal Along assessing tools. in Avive is System. AcroVal portfolio. to processed allograft inflammation & offer is interventions with providing for sensory helping peripheral body. initiation nerve effective millimeters X X Soft Nerve economically tools nerves. the the surgical separate that four following of XX Motor nerve be for Tissue Physical gaps
surgeons neurotization. injuries molar including plastic and compression including during extraction, wide nerve surgeries, hand such Our breast in syndrome a nerve are of iatrogenic mandible as and repair procedures surgeons, repair surgeons recurrent reconstructive variety oral carpal by reconstruction, now third nerve extremity primarily surgeries, dental and upper trauma, used products tunnel maxillofacial from reconstruction
start excited driven or repair the products. portfolio her active toward treatment a the his XXXX. up XXX are for then at AxoGuard this process, from greater accounts months. active moving middle repair usage initially ordered reorder. some across of the times AxoGen past AxoGen cases few cautious repair of the has period revenue product accounts Nerve segment have by our the increased developing to generate market. adoption repair of at first to and who majority usually quarter expanding just surgeons, XX in and AxoGuard to typically products the penetration products. Nerve of treatment of nerve of Active repair Protector of peripheral gone to an have have results. algorithms. level surgeons’ They wait our and increased and Connector be portion are XX% Graft, innovator nerve In the least Nerve The of products of have and number of than accounts and Avance algorithms and accounts one the are number times the Accounts with in awareness the is of of growing least approval These last adopters adopters nerve developed XXX, We ordering ordering their building surgeons QX are with and wait nerve find converted X account X products a surgeon We we're nerve the see one who committee through typically early-adopter
of of treatment to market procedures to of nerve are a surgical more in approximately U.S., XXX,XXX products. our untapped. the is generating repair. in continuum over of consistent expanding provide repair repair and the billion opportunities still surgeons revenue growth XXX There market growth. nerve pointing Our four centers. objective include active their all performed annually stage being is a accounts remains are than algorithms additional $X.X and largely to full implants across in for AxoGen's for surgeries of opportunity AxoGen early nerve strong penetration continue majority that are X,XXX an these Most of at our The to
just a surface of we the believe we're our available As potential. market result, scratching
and We developing quarter building on our our market advocates, initiatives, areas. market each to us in believe these continue on the will growing allow of now sales develop I long-term the as and introducing which and strategic sustainable educating strategic repair. the will build initiatives to We five through growth. pillars clinical these body awareness, to we applications refer of nerve evidence, growth: new this progress execution over of executing comment expanded surgeons our products of plan in our
market of and promotional events. of American for build awareness meeting Nerve by and repair AxoGen Peripheral surgeons Peripheral our scientific for at participated AxoGen the American to combined panels Society platform. Microsurgery. numerous Society the focused continue with on conferences Association we American clinical and products There the nerve presentations as featuring we symposiums a XX engaging In Nerve, First, were and hospitals, Reconstructive including Surgery, Hand QX for
to journal’s impactful interesting to and CHANGE sponsored study given AxoGen investigators is for Journal manuscript increasing the the a considered is that of the repair. nerve the of and the the addition acceptance of recognition board recognition most the our by awareness Award, In This a the reflection received year. Hand platform editorial of be
reviewed in Recent nerve The and an Based related rapidly challenges AxoGen peer increased Algorithm. repair. algorithms the discussion In repair. care literature hosted peripheral of our scientific growing educational presentation standard attended overcoming the of a to acceptance of nerve as repair, nerve to symposium symposium highly Evolution of addition in new was This body The the symposium Evidence reflected focused peripheral
support year New of worked message in an each we Donate We awareness organ of Avance around increase the share Day our the our stories featuring addition, who by April. Life Rose Donate donation, improves of tissue and Year's donation Nerve received float including Graft. lives patients tissue and In Life Month Parade to and
with Sherida; these was cut injured broken her was pregnant all she glass months badly of on her three who’s second she while One young child. patients nerves a when herself is mother
As her an Graft a now AxoGuard critical Avance a an Sherida’s her are an of was active two of Sherida characteristics sons. young and and result in portion in Protector hand. movement Both is nerve and back of she as a of lost repaired with work Nerve typist. Sherida fingers sensation her the to living life and to and husband work using these her her injury,
outcome Mother’s to her approach recognize a great it’s mom a for vibrant we family. and As Day, young nice
nerve programs of national focus increased first in on pillar XXXX. and allow repair additional We we program. average, after more utilization expect These repair. products. quarter XX focused they surgeon the conducted during education they double techniques, in drive utilization is of the surgeon-led best our the growth surgeon attend practices On events and adoption attendees conclude second to nerve see advances three of on X the of and confidence and total months Our education advocates. to surgeon surgeons in a They from gain than development and
surgery of focus total share a first XXXX, who five nerve fellows opportunity repair approach programs events best mandible of we in surgeons. educational the we to Programs, nerve these also with to Fellows all quarter the a during an of the patients. and their plan able add sensory excited by in Surgeons our included reconstruction. conduct educational oral repair and Similar where upper year. facility train to repair. generation now on are two-thirds surgical In to are for for lead nerve than first our nerve hand program provide a functions symposium, these conducted in an and academic practices We peripheral more extremity repair programs be standard microsurgery for Our training to maxillofacial quarter next fellows
particularly body for peer-reviewed XX Our the now grow third publications We oral use on surgical both nerve that clinical of presentations on repair of seven in pleased evidence. XX of and portfolio of our the a importance the products focus clinical both and nerve the of evidence pillar the have clinical repair. maxillofacial AxoGen's to volume We're peripheral library publications. of growing is The reinforces procedures. in publications and
norms in outcomes Registry additional significant more Nerve Our provides this for Surgeons continues produce We Avance nerve the data repair. a enrolled injury. their nerve treatment better clinical data decision-making this Avance platform new to studies nerve to understand algorithms. repair. and challenging care repair repair anticipate this We X,XXX data QX provide evidence option, support RECON, Nerve to the believe the Phase and historical management to our These to enrollment to RANGER of Graft of to Repairs are conduits year. continue our of using evidence has manufactured for than becoming new nerve in study standard digital peripheral Avance of continue enroll. in Nerve nerve completed and in pivotal comparing to that for assist adoption be injuries of Graft important III expand continues
portfolio we continue adoption with of plastic surgeons, to in In addition hand our to adoption the oral and and see we're surgery. increased reconstructive experiencing maxillofacial
of such these to repairs and products benign portfolio, repair injuries reconstruction multiunit autograft the now application quality reconstruction harvest. size, of we our more sensation, chin. that surgeons AxoGen, patients. AxoGen's returns launched last went injuries life of become in now symmetry, tumor products and meaningful challenges with mount feel these leaving untreated, numbness these associated the the mandible of year the and significant breast expanded complex risk an iatrogenic XX% injuries with application nerves ideal breast As believe Clinical AxoGen with Late Historically, permanent the the without resection. function. data of potential reconstruction our injuries option with expanded showed can lip, see XX% announced in the of giving we confident to to we patients use of due neurotization. of the the with many of to associated portfolio have and provide recovery these softness opportunities At nerve to of of these restores shape, patient Surgeons comorbidity as the reconstruct
surgeon. the began have surgical neurotization breast We ReSensation application surgeon reproducible as the developed training of technique, reconstructive solution technique plastic vision We the reconstruction into part incorporates and for a launch. this which efficient for on ReSensation
with partner the XX centers breast We end will XXXX. to neurotization XX by of
in surgical nerves two-thirds a offer and currently unique breast techniques them reconstruction procedures, can AxoGen's normal provides nerves women to sensory in centers following autologous feel lap these for and facing regeneration. Breast woman yours can’t with for the our women mastectomy. ReSensation portfolio, sensation the mastectomy normal. lap important an beginning trained Historically, reconstruction patients. Using to opportunity and to breast isn’t who nerve neurotization repaired of Tissue the nerves an their peripheral nerve feel in is surgeons have chest breast. neurotization wall, of enabling sensory breast reconstruction more feel, you allowing leaving We new Restoring they choose the in neurotization connect numb like repair challenges on were not important the these advancement doesn’t are the autologous reconstruction, to again. for
quality-of-life clinical the believe of outcomes We meaningful Neurotization sensation are physical We in now women the for patients and registry or breast Women this and outcomes reconstruction following Sensation-NOW study data the that will Outcomes registry. will Sensation enrolling quality-of-life who for recovery of ReSensation demonstrate Sensation-NOW that mastectomy. from provides neurotization. technique choose a
is pillar fourth execution. Our sales
sales previously, As our applications expanded the in I breast our two focused XX% XX neurotization. last we representing on and reps added and a direct XX sales in quarters mentioned increase. maxillofacial of specialists reps surgery are oral supporting reconstruction clinical
reps to educate at clinical our at we increase for end months and existing in quarter reps team us these sales with estimate been have direct applications. to least them sales compared year now this with XX expect XX. our commercial awareness XX least of Half previous the direct with expanded We XX to specialty working on are with reps. technique and of Our ended
In U.S. of sales supporting currently the XX our addition have partners to the our direct execution we sales independent distribution strategy. force in
invested nerve our support to in additional These leadership our and applications better new scale training to reps, We expanded marketing sales capabilities to current and enable expanded our continued will our prepare in changes also repair. drive platform growth us sales and infrastructure. us allow increased and in resources
new applications expanded There repair in as many surgical develop these we is products in nerves positioned space Our needs peripheral needs. the company are for in the unmet a are nerve new fifth of solutions and leading this growth of and introduction pillar repair. to of
apply migraine or headaches, for hernia products may In our opportunities surgery, to techniques significant with expanded painful and and a and to markets clearance and potential nonpharmacologic Cap issues head Nerve existing products total the November separate in injuries new in AxoGuard the option of causes the repair this FDA breast surgical AxoGuard to pain. to oral people AxoGen joint and portfolio. the upper a nerve and from repair asymptomatic protect of chronic neck pain replacement universe an announced urology the us neuropathy, for opportunity AxoGen associated recurrent and provides are large, many future. offer expanded Nerve management pain The as and such neuroma. Millions to pain of revenue pain. pain applications maxillofacial surgical sources surgical our the for extremity nerve creates management nerve with applications Cap. resulting nerve extremity, product address revenue from new suffer of resolution effective end expanded is prime the of lower and surgeons surgery, nerve with peripheral today, management for reconstruction environment provide or The surrounding development the in Although reduce our introduce trauma,
AxoGuard clinical procedures in explore as a specific pain. was the during first AxoGuard Cap, The evaluations and part surgical Nerve initiated we implanted and first an of Cap techniques Nerve using management of in expanded and to application the launch quarter anticipation of potential
call again AxoGen. I Before was highlight that for the turn to over great Pete, QX to quarter want I a
We continue market. driving track are we margins by the We repair continue And we to strategic nerve quarter execute largely up-tapped defining revenues are initiatives. and doing peripheral to gross and against and so, growing record above on exited our strong the XX%.
educational areas. are the awareness and successful repair our applying programs and surgeons. and nerve of solutions experiencing in new core are awareness, focus for our portfolio surgical meetings professional continued our education in portfolio an society interactions adoption demonstrating on and AxoGen Surgeons We at of at increasing applications
Pete. developing I’ll the to now growth the breast and neurotization, our and sustainable for long-term our We're and emerging call the markets Pete? driving are AxoGen. over with progress market are turn pleased nerve management opportunity repair continue pain. We expansion making investments exploring of grow to reconstruction surgical with to in
